Dr. Daniel Breadner

Medical Oncologist & Cancer Researcher in London, Ontario, Canada

[Dr. Daniel Breadner @DrDanBreadner]

Happy to share an article demonstrating our results from years of profiling tumours (beyond the standard of care) for patients with advanced disease.

https://t.co/msDOZnwtgB

[Mario Balsa @MarioBalsaMD]

💎 #ESMO25 Presidential Session w/ @JeanneTie #ColorectalCancer – Phase III DYNAMIC-III: ctDNA-guided de-escalation after surgery in stage III colon cancer

In ctDNA⁻ patients:
☄️ 3-year RFS 85.3% vs 88.1% (standard)
🎯 Oxaliplatin exposure reduced 88.6% ➜ 34.8%
💥 Fewer hospitalizations & grade ≥3 AEs
👍🏼 High adherence (90%)

Precision meets pragmatism! Sometimes, less is truly more…dynamically ✨

@OncoAlert #OncoAlertAF @OncoReporte @myESMO @_SEOM @GrupoTTD

[Midhun Malla @MallaMidhun]

DYNAMIC III deescalation study presented #esmo2025 did not meet prespecified endpoint, although missed it narrowly. Chemotherapy continues to be SOC for stage III colon cancer patients. #clinicaltrials Congratulations to Dr.Tie for her inspirational work in this field.

[Dr. Daniel Breadner @DrDanBreadner]

Honoured to present OCELOT data today @IASLC #WCLC2025 #LCSM on behalf of my Canadian coauthors.

[Dr. Daniel Breadner @DrDanBreadner]

Learning about the gut microbiome at #WCLC2024 with @ArielleElkrief

[Dr. Daniel Breadner @DrDanBreadner]

Great work Dr. Verma and the whole POWER team on this work. HER2 is not just for breast and stomach cancer, and the results are not binary +'ve(3+/2+ with ISH+) versus -'ve anymore.
https://t.co/CgXcOPkJdY

[Dr. Daniel Breadner @DrDanBreadner]

@NiuSanford @aadel_chaudhuri We observed the same, even after only hours with lower RT doses or chemo. https://t.co/qBpc4otrQa
We are looking at this in 90 patients getting radical SBRT for stage I lung cancer. https://t.co/HMhSCxhqku
with @drdavidpalma @DrAlexLouie

[Dr. Daniel Breadner @DrDanBreadner]

Strong work by Drs. Saurav Verma and Mark Vincent, honoured to have been included.
An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy https://t.co/G20BkrDe7q #mdpicancers via @Cancers_MDPI

[Dr. Daniel Breadner @DrDanBreadner]

Fellow Lung Cancer Researchers, if you are interested in publishing a review, editorial or original research on combination therapies in lung cancer in the official journal of @CAMO_ACOM Please reach out!

[Dr. Daniel Breadner @DrDanBreadner]

I had the privilege of collaborating with a group of Canadian experts, myself included, on a self-learning video platform. Our focus revolved around the management of oncology patients, and I encourage you to explore the video library available : https://t.co/5RuQ9QTKDN

[Saurav Verma @SauraVermaMD]

Sharing our review discussing efficacy, safety and future with ADCs in NSCLC - ‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review https://t.co/WJCtLCT7QQ #mdpicurroncol via @CurrentOncology @JackRaph @DrDanBreadner

[Dr. Daniel Breadner @DrDanBreadner]

#boat2023 @OncEd is a great way to get the updates from ASCO AM across disease sites. And thrilled to be presenting updates along with Dr. Stephen Welch to represent LRCP @LHSCCanada
A must attend for all medical oncologists, even if they were in Chicago

[Pierre-Olivier Gaudreau MD PhD @DrPOGaudreau]

(1/3) Going to ASCO this week? Join us for Dr. Quincy Chu's oral presentation highlighting the phase 3 results of the IND.227 trial in mesothelioma:
Time: Jun/3/2023, 3:00 PM-6:00 PM CDT Hall B1
https://t.co/HnpVyxeoaW
@INDProgramCCTG @CDNCancerTrials #mesothelioma

[Dr. Daniel Breadner @DrDanBreadner]

Excited to see Dr Quincy Chu presenting IND227 at ASCO. @CDNCancerTrials @INDProgramCCTG

[CTCR @WesternU_CTCR]

Congratulations to members @DrDanBreadner, Dr. Scott Ernst, Dr. Maria MacDonald, and Dr. Mark Vincent of @SchulichMedDent and @LHSCCanada for their recent MORF Grant funding. #ResearchMatters

[Dr. Daniel Breadner @DrDanBreadner]

@WesternU_CTCR @SchulichMedDent @LHSCCanada Thank you so much for sharing!

[London Health Sciences Centre @LHSCCanada]

Dr. Breadner explains why pancreatic cancer is still one of the more challenging cancers to diagnose and treat, and the importance of the work being done by researchers at The Baker Centre for Pancreatic Cancer. 

Learn more: https://t.co/zpZy5VlO8y

[Paul Wheatley-Price @pwheatleyprice]

Huge disappointment: @NovartisCanada & pan-Canadian pharmaceutical alliance (pCPA) failed to negotiate a dabrafenib/tremetinib price in BRAF+ lung ca. https://t.co/nRircqeBCX Bewildering as an agreement exists in melanoma. Lung ca pts being stigmatized - again? @LungCancer_Can